PINNED
PINNED
New year, new cell and gene therapy collaborations
Here we run down four new research collaborations in the cell and gene therapy sector, announced by Bayer, BMS, Pfizer and Moderna.
List view / Grid view
Articles
Embedding inclusion in pharmaceutical design
In this article, Included’s Raafi-Karim Alidina explores biases in product design, outlining how they impact pharmaceuticals as well as technologies, and practical steps to enhance diversity and ensure inclusion.
Six major disruptors for the generics and biosimilars market
In this article, EPR's Hannah Balfour outlines six factors that could significantly challenge the generics and biosimilars market in the next decade.
‘Magic bullets’ for all: democratising biologics by rethinking antibody development, manufacturing and delivery
Antibody therapeutics revolutionised how diseases like cancer are treated in the developed world, but their high manufacturing cost and cumbersome distribution and administration leave them out of reach for most. In this guest article, Lumen Bioscience’s CEO, Brian Finrow, and EVP of Production & Development, Craig Behnke, discuss how new…
Principal component analysis of Raman spectra for freeze-drying process monitoring
Optical spectral measurement tools are extremely useful both for in-line measurements in process analytical techniques (PATs) as well as for evaluating the composition of finished substances. Here, CPI’s Lukas Kuerten and Rachel Findlay demonstrate a valuable method for gaining useful information from spectral data.
UK life sciences sector: do you have the Vision for innovation?
Here, EPR’s Hannah Balfour explores some highlights of the UK’s new Life Sciences Vision for the pharma, biopharma and biotech industries, covering topics from funding to regulatory reviews and clinical trial innovation.
Paediatric medicines: just a spoonful of sugar?
Here, Dave Elder discusses the ever increasing importance of child-friendly medications and the specific challenges associated with their development.
The research-based industry response to COVID-19; collaboration and innovation
Nathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) gives her take on the industry response to the pandemic; highlighting the benefits of focused effort and what can be achieved through unified collaboration.
Improving infusion dosing accuracy for patient safety
Infusion is the most used technology in hospitals. Given its widespread application, often in critical situations and by many users, infusion errors are frequently made, with some having severe effects. Here, Emmelyn Graham, Flow Measurement Engineer at TÜV SÜD National Engineering Laboratory, and Elsa Batista, Head of Volume and Flow…
Improvements in skin and nail drug delivery using nano formulations
It might be easy to dismiss non-life-threatening diseases of the skin or nail as trivial, but their impact on physical and mental wellbeing can be significant. Such diseases are obvious targets for topical treatments, but the lack of effective formulations means patients are often faced with the prospect of oral…
Achieving sustainable innovation with value-added medicines
The COVID-19 pandemic spotlighted drug repurposing as a key strategy to support traditional novel chemical entity development; yet repurposing is just one example of how off-patent molecules can be further developed to provide patients with more treatment options. Here, Arun Narayan, Chairman of the Value Added Medicines Sector Group at…
![Researcher looking at an experiment [Credit: Unsplash].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Bell-advanced-therapies-feature-300x278.jpg)
![Researcher looking at an experiment [Credit: Unsplash].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Bell-advanced-therapies-feature.jpg)
UK at the forefront of advanced therapies
Advanced therapies are a ground-breaking new class of medicines that use gene therapy, cell therapy or tissue engineering to treat disease and injury. Rachel Bell, Trainee Patent Attorney at Marks & Clerk, and Ceri Roberts, Scientific Training Manager – Cellular and Molecular Therapies at NHS Blood and Transplant, discuss some…
Taking cell and gene therapies from idea to commercialisation
David Vincent, Process Development Lead at eXmoor Pharma, details some of the critical steps that form the manufacturing strategy for providers of cell and gene therapies.
Manufacturing, Packaging & Logistics In-Depth Focus 2021
Features in this in-depth focus highlight some of the important developments in the cell and gene therapy market, as well as the key manufacturing strategies to consider when taking them from concept to commercialisation.
QA/QC & Environmental Monitoring In-Depth Focus 2021
In this in-depth focus, learn how to overcome interfering factors when using LAL for endotoxin testing and discover how the implementation of a new scrubs system benefited an aseptic production facility.
Formulation, Development & Delivery In-Depth Focus 2021
Featured in this in-depth focus: why improving dosing accuracy with infusion pumps requires users to have a better understanding of the equipment and how nanomedicines could be instrumental in improving skin and nail diseases.